Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: BMC Cancer 2011, 11:21
- Schlagwort
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Univ.-Bibliothek Frankfurt am Main
- (wann)
-
2011
- Beteiligte Personen und Organisationen
-
Simon, Thorsten
Hero, Barbara
Faldum, Andreas
Handgretinger, Rupert
Schrappe, Martin
Klingebiel, Thomas
Berthold, Frank
- URN
-
urn:nbn:de:hebis:30-90395
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:53 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Simon, Thorsten
- Hero, Barbara
- Faldum, Andreas
- Handgretinger, Rupert
- Schrappe, Martin
- Klingebiel, Thomas
- Berthold, Frank
- Univ.-Bibliothek Frankfurt am Main
Entstanden
- 2011
Ähnliche Objekte (12)
Chemotherapy and immunotherapy of malignat gliomas
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Functional validation of novel target structures for treatment of high-risk neuroblastoma
Classical mathematical models for prediction of response to chemotherapy and immunotherapy
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
SMAC mimetics as a novel strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
In vitro and in vivo characterization of antibody based PET tracers for imaging of neuroblastoma
Chemotherapy and immunotherapy of malignat gliomas
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Functional validation of novel target structures for treatment of high-risk neuroblastoma
Classical mathematical models for prediction of response to chemotherapy and immunotherapy
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
SMAC mimetics as a novel strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
In vitro and in vivo characterization of antibody based PET tracers for imaging of neuroblastoma
Chemotherapy and immunotherapy of malignat gliomas
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Functional validation of novel target structures for treatment of high-risk neuroblastoma
Classical mathematical models for prediction of response to chemotherapy and immunotherapy
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
SMAC mimetics as a novel strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients